BioSpace News Archive

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that the Company has expanded its Clinical Operations Team with the hiring of a Director of Clinical Operations, a Senior Manager of Clinical Trials, and a Senior Director of Biometrics.

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, announced the Company will provide a corporate update and report second quarter 2021 financial results on Monday, August 16.

23andMe Holding Co., a leading consumer genetics and research company, reported its financial results for the first quarter of its fiscal year 2022, which ended June 30, 2021.

Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, reported financial and operating results for the three and six months ended June 30, 2021.

Expansion in rates of Genetic problems and malignancy, flood in mindfulness and acknowledgment of customized medications, and headways in genetic testing procedures fuel the development of the worldwide genetic testing market.

Increased use to improve body composition, muscle & bone growth, body fluids, sugar & fat metabolism, and recovery from injury is expected to propel the market growth.

Expansion in occurrences of ongoing and irresistible infections, innovative headways in IVD, ascend in reception of in vitro analytic testing, flood in government consumption on medical care, and fame of customized medication approach fuel the development of the worldwide In Vitro Diagnostics (IVD) market.

Brooklyn ImmunoTherapeutics, Inc., a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, announced that Chief Executive Officer Howard J. Federoff, M.D., Ph.D., will present a corporate overview at the SNN Virtual Investor Conference being held August 17 – 19, 2021.

Rani Therapeutics Holdings, Inc. (Nasdaq:RANI) (“Rani Therapeutics” or “Rani”), a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics today announced the final closing of its initial public offering of 7,666,667 shares of its Class A common stock,

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2021.